Sanofi Ends Marketing Deal With Developer of Inhaled Insulin
The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent. The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent.